153 related articles for article (PubMed ID: 33818823)
1. Population pharmacokinetics and probability of target attainment in patients with sepsis under renal replacement therapy receiving continuous infusion of meropenem: Sustained low-efficiency dialysis and continuous veno-venous haemodialysis.
Westermann I; Gastine S; Müller C; Rudolph W; Peters F; Bloos F; Pletz M; Hagel S
Br J Clin Pharmacol; 2021 Nov; 87(11):4293-4303. PubMed ID: 33818823
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of meropenem in septic patients on sustained low-efficiency dialysis: a population pharmacokinetic study.
Braune S; König C; Roberts JA; Nierhaus A; Steinmetz O; Baehr M; Kluge S; Langebrake C
Crit Care; 2018 Jan; 22(1):25. PubMed ID: 29382394
[TBL] [Abstract][Full Text] [Related]
3. Optimal Dosing of Meropenem in a Small Cohort of Critically Ill Children Receiving Continuous Renal Replacement Therapy.
Tan WW; Watt KM; Boakye-Agyeman F; Cohen-Wolkowiez M; Mok YH; Yung CF; Chan YH
J Clin Pharmacol; 2021 Jun; 61(6):744-754. PubMed ID: 33314163
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of standard-dose meropenem in critically ill patients on continuous renal replacement therapy: a prospective observational trial.
Onichimowski D; Będźkowska A; Ziółkowski H; Jaroszewski J; Borys M; Czuczwar M; Wiczling P
Pharmacol Rep; 2020 Jun; 72(3):719-729. PubMed ID: 32301057
[TBL] [Abstract][Full Text] [Related]
5. The combined effects of extracorporeal membrane oxygenation and renal replacement therapy on meropenem pharmacokinetics: a matched cohort study.
Shekar K; Fraser JF; Taccone FS; Welch S; Wallis SC; Mullany DV; Lipman J; Roberts JA;
Crit Care; 2014 Dec; 18(6):565. PubMed ID: 25636084
[TBL] [Abstract][Full Text] [Related]
6. Use of Monte Carlo Simulations to Determine Optimal Carbapenem Dosing in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy.
Lewis SJ; Kays MB; Mueller BA
J Clin Pharmacol; 2016 Oct; 56(10):1277-87. PubMed ID: 26919659
[TBL] [Abstract][Full Text] [Related]
7. Optimized meropenem dosage regimens using a pharmacokinetic/pharmacodynamic population approach in patients undergoing continuous venovenous haemodiafiltration with high-adsorbent membrane.
Padullés Zamora A; Juvany Roig R; Leiva Badosa E; Sabater Riera J; Pérez Fernández XL; Cárdenas Campos P; Rigo Bonin R; Alía Ramos P; Tubau Quintano F; Sospedra Martinez E; Colom Codina H
J Antimicrob Chemother; 2019 Oct; 74(10):2979-2983. PubMed ID: 31335959
[TBL] [Abstract][Full Text] [Related]
8. Acute-on-chronic liver failure alters meropenem pharmacokinetics in critically ill patients with continuous hemodialysis: an observational study.
Grensemann J; Busse D; König C; Roedl K; Jäger W; Jarczak D; Iwersen-Bergmann S; Manthey C; Kluge S; Kloft C; Fuhrmann V
Ann Intensive Care; 2020 Apr; 10(1):48. PubMed ID: 32323030
[TBL] [Abstract][Full Text] [Related]
9. Meropenem population pharmacokinetics in critically ill patients with septic shock and continuous renal replacement therapy: influence of residual diuresis on dose requirements.
Ulldemolins M; Soy D; Llaurado-Serra M; Vaquer S; Castro P; Rodríguez AH; Pontes C; Calvo G; Torres A; Martín-Loeches I
Antimicrob Agents Chemother; 2015 Sep; 59(9):5520-8. PubMed ID: 26124172
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic drug monitoring-guided continuous infusion of piperacillin/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience.
Richter DC; Frey O; Röhr A; Roberts JA; Köberer A; Fuchs T; Papadimas N; Heinzel-Gutenbrunner M; Brenner T; Lichtenstern C; Weigand MA; Brinkmann A
Infection; 2019 Dec; 47(6):1001-1011. PubMed ID: 31473974
[TBL] [Abstract][Full Text] [Related]
11. Meropenem dosing recommendations for critically ill patients receiving continuous renal replacement therapy.
Chaijamorn W; Rungkitwattanakul D; Pattharachayakul S; Singhan W; Charoensareerat T; Srisawat N
J Crit Care; 2020 Dec; 60():285-289. PubMed ID: 32949895
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients.
Mattioli F; Fucile C; Del Bono V; Marini V; Parisini A; Molin A; Zuccoli ML; Milano G; Danesi R; Marchese A; Polillo M; Viscoli C; Pelosi P; Martelli A; Di Paolo A
Eur J Clin Pharmacol; 2016 Jul; 72(7):839-48. PubMed ID: 27048201
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy.
Isla A; Rodríguez-Gascón A; Trocóniz IF; Bueno L; Solinís MA; Maynar J; Sánchez-Izquierdo JA; Pedraz JL
Clin Pharmacokinet; 2008; 47(3):173-80. PubMed ID: 18307371
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of fluconazole in critically ill patients receiving extracorporeal membrane oxygenation and continuous renal replacement therapy: an ASAP ECMO study.
Novy E; Abdul-Aziz MH; Cheng V; Burrows F; Buscher H; Corley A; Diehl A; Gilder E; Levkovich BJ; McGuinness S; Ordonez J; Parke R; Parker S; Pellegrino V; Reynolds C; Rudham S; Wallis SC; Welch SA; Fraser JF; Shekar K; Roberts JA
Antimicrob Agents Chemother; 2024 Jan; 68(1):e0120123. PubMed ID: 38063399
[TBL] [Abstract][Full Text] [Related]
15. The Effect of Renal Replacement Therapy and Antibiotic Dose on Antibiotic Concentrations in Critically Ill Patients: Data From the Multinational Sampling Antibiotics in Renal Replacement Therapy Study.
Roberts JA; Joynt GM; Lee A; Choi G; Bellomo R; Kanji S; Mudaliar MY; Peake SL; Stephens D; Taccone FS; Ulldemolins M; Valkonen MM; Agbeve J; Baptista JP; Bekos V; Boidin C; Brinkmann A; Buizen L; Castro P; Cole CL; Creteur J; De Waele JJ; Deans R; Eastwood GM; Escobar L; Gomersall C; Gresham R; Jamal JA; Kluge S; König C; Koulouras VP; Lassig-Smith M; Laterre PF; Lei K; Leung P; Lefrant JY; Llauradó-Serra M; Martin-Loeches I; Mat Nor MB; Ostermann M; Parker SL; Rello J; Roberts DM; Roberts MS; Richards B; Rodríguez A; Roehr AC; Roger C; Seoane L; Sinnollareddy M; Sousa E; Soy D; Spring A; Starr T; Thomas J; Turnidge J; Wallis SC; Williams T; Wittebole X; Zikou XT; Paul SK; Lipman J;
Clin Infect Dis; 2021 Apr; 72(8):1369-1378. PubMed ID: 32150603
[TBL] [Abstract][Full Text] [Related]
16. Meropenem pharmacokinetics during extracorporeal membrane oxygenation and continuous haemodialysis: a case report.
Saito J; Shoji K; Oho Y; Aoki S; Matsumoto S; Yoshida M; Nakamura H; Kaneko Y; Hayashi T; Yamatani A; Capparelli E; Miyairi I
J Glob Antimicrob Resist; 2020 Sep; 22():651-655. PubMed ID: 32417590
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration.
Giles LJ; Jennings AC; Thomson AH; Creed G; Beale RJ; McLuckie A
Crit Care Med; 2000 Mar; 28(3):632-7. PubMed ID: 10752806
[TBL] [Abstract][Full Text] [Related]
18. Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study.
Ehmann L; Zoller M; Minichmayr IK; Scharf C; Maier B; Schmitt MV; Hartung N; Huisinga W; Vogeser M; Frey L; Zander J; Kloft C
Crit Care; 2017 Oct; 21(1):263. PubMed ID: 29058601
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics and simulations of imipenem in critically ill patients undergoing continuous renal replacement therapy.
Li S; Xie F
Int J Antimicrob Agents; 2019 Jan; 53(1):98-105. PubMed ID: 30626495
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of meropenem in children with sepsis undergoing extracorporeal life support: A prospective observational study.
Wang Y; Li Z; Chen W; Yan G; Wang G; Lu G; Chen C
J Clin Pharm Ther; 2021 Jun; 46(3):754-761. PubMed ID: 33476064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
